



## Seres Therapeutics to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on February 25, 2016

February 16, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 16, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, February 25, 2016 at 8:30 a.m. EST to discuss fourth quarter and full year 2015 financial results.

To access the conference call, please dial 888-834-1266 (domestic) or 440-996-5713 (international) and reference the conference ID number 51996167. To join the live webcast please visit the "Investors and Media" section of the Seres website at [www.serestherapeutics.com](http://www.serestherapeutics.com).

A webcast replay with corresponding slides will be available on the Seres website beginning approximately two hours after the event and will be archived for 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome characterized by an increased presence of pathogenic bacterial species, where the natural state of bacterial diversity is imbalanced. Seres' most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring *Clostridium difficile* infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC).



View source version on businesswire.com: <http://www.businesswire.com/news/home/20160216006780/en/>

Source: Seres Therapeutics, Inc.

#### IR Contact:

Seres Therapeutics,  
Carlo Tanzi, Ph.D., 617-203-3467  
Head of Investor Relations and Corporate Communications  
[Ctanzi@serestherapeutics.com](mailto:Ctanzi@serestherapeutics.com)

or

#### PR Contact:

Ten Bridge Communications,  
Dan Quinn, 781-475-7974  
[Dan@tenbridgecommunications.com](mailto:Dan@tenbridgecommunications.com)